Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine.
Nantel S, Bourdin B, Adams K, Carbonneau J, Rabezanahary H, Hamelin MÈ, McCormack D, Savard P, Longtin Y, Cheng MP, De Serres G, Corbeil J, Gilca V, Baz M, Boivin G, Quach C, Decaluwe H. Nantel S, et al. Among authors: mccormack d. Front Immunol. 2022 Oct 14;13:930252. doi: 10.3389/fimmu.2022.930252. eCollection 2022. Front Immunol. 2022. PMID: 36311736 Free PMC article.
The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers.
Racine É, Boivin G, Longtin Y, McCormack D, Decaluwe H, Savard P, Cheng MP, Hamelin MÈ, Carbonneau J, Tadount F, Adams K, Bourdin B, Nantel S, Gilca V, Corbeil J, De Serres G, Quach-Thanh C. Racine É, et al. Among authors: mccormack d. Influenza Other Respir Viruses. 2022 Sep;16(5):916-925. doi: 10.1111/irv.12997. Epub 2022 May 5. Influenza Other Respir Viruses. 2022. PMID: 35510653 Free PMC article.
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.
Colmegna I, Valerio V, Amiable N, Useche M, Rampakakis E, Flamand L, Rollet-Labelle E, Bessette L, Fitzcharles MA, Hazel E, McCormack D, Michou L, Panopalis P, Langlois MA, Bernatsky S, Fortin PR. Colmegna I, et al. Among authors: mccormack d. RMD Open. 2023 Nov 29;9(4):e003400. doi: 10.1136/rmdopen-2023-003400. RMD Open. 2023. PMID: 38030231 Free PMC article. Clinical Trial.
Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial.
Colmegna I, Useche ML, Rodriguez K, McCormack D, Alfonso G, Patel A, Ramanakumar AV, Rahme E, Bernatsky S, Hudson M, Ward BJ. Colmegna I, et al. Among authors: mccormack d. Lancet Rheumatol. 2020 Jan;2(1):e14-e23. doi: 10.1016/S2665-9913(19)30094-3. Epub 2019 Nov 20. Lancet Rheumatol. 2020. PMID: 38258270
Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12- to 18-month-old children.
Noya F, McCormack D, Reynolds DL, Neame D, Oster P. Noya F, et al. Among authors: mccormack d. Can J Infect Dis Med Microbiol. 2014 Jul;25(4):211-6. doi: 10.1155/2014/237560. Can J Infect Dis Med Microbiol. 2014. PMID: 25285126 Free PMC article.
Case-control study of household contacts to examine immunological protection from Bordetella pertussis transmission - study protocol.
Bolotin S, Johnson C, Quach S, Ambrose A, DeCoutere S, Deeks SL, Drews S, Faheem A, Green K, Halperin SA, Hoang L, Jamieson F, Kollmann T, Marchand-Austin A, McCormack D, McGeer A, Murti M, Bba AO, Rebbapragada A, Vanderkooi OG, Wang J, Warshawsky B, Crowcroft NS; Canadian Immunization Research Network Provincial Collaborative Network. Bolotin S, et al. Among authors: mccormack d. CMAJ Open. 2017 Dec 19;5(4):E872-E877. doi: 10.9778/cmajo.20170072. CMAJ Open. 2017. PMID: 29269437 Free PMC article.
432 results